Home
Resources
Diseases
COVID-19
Hepatitis B
Human papillomavirus (HPV)
Malaria
Measles
Mpox
Pneumococcal disease
RSV (Respiratory syncytial virus)
Compendium
Hexavalent vaccines
HPV vaccines
Malaria vaccines
PCV vaccines
RSV vaccines
Training
Vaccine Portfolio Optimization and Prioritization (VPOP)
Evaluation
The Tool
The Tutorial
The Dashboard
SYSVAC
About
Registry
E-learning courses
News
Webinars
Network
Steering Committee
Vision and Mission
Map
Meetings
Partners
Join us
Home
Resources
Resources
Selected
COVID-19
Type of publications
Guidelines (1)
NITAG documentation (359)
Reports (1)
SAGE documentation (34)
Scientific publications (4)
Systematic reviews (SYSVAC) (1190)
Regions
Africa (62)
Americas (192)
Eastern Mediterranean (12)
Europe (160)
Global (1)
South-East Asia (11)
Western Pacific (39)
Diseases
COVID-19 (1589)
Chikungunya (13)
Cholera (35)
Cytomegalovirus (1)
Dengue (43)
Diphtheria (90)
Ebola (19)
Escherichia coli (ETEC) (2)
Haemophilus influenzae type B (71)
Hepatitis A (69)
Hepatitis B (171)
Hepatitis C (5)
Hepatitis E (5)
Herpes simplex (1)
Herpes zoster (77)
HIV / AIDS (10)
Human papillomavirus (HPV) (537)
Influenza (629)
Japanese encephalitis (34)
Lyme disease, Borreliosis (2)
Malaria (33)
Measles (144)
Meningococcal disease (155)
Moraxella catarrhalis (1)
Mpox (58)
Mumps (50)
Pertussis (120)
Pneumococcal disease (305)
Poliomyelitis (94)
Q fever (1)
Rabies (33)
Rotavirus (121)
RSV (Respiratory syncytial virus) (69)
Rubella (69)
Salmonella (3)
Shigella (1)
Smallpox (16)
Streptococcus group B (6)
Tetanus (71)
Tick-borne encephalitis (14)
Tuberculosis (83)
Typhoid (32)
Varicella (77)
Yellow fever (44)
Zika (1)
Show more
Methodological quality (AMSTAR 2)
High (13)
Moderate (9)
Low (130)
Critically low (729)
Not applicable (309)
1589 results found
2022
∙
Health Council of the Netherlands
Executive summary of the Second booster vaccination against COVID-19
2022
∙
ATAGI
Expanded ATAGI recommendations on winter COVID-19 booster doses for people at increased risk of severe COVID-19
2022
∙
ACIP
GRADE for Moderna COVID-19 Vaccine for Children Aged 6 Months–5 Years
2022
∙
ACIP
GRADE for Pfizer-BioNTech COVID-19 Vaccine for Children Aged 6 Months–4 Years
2022
∙
NACI
Initial guidance on a second booster dose of COVID-19 vaccines in Canada
2022
∙
Elisha Hall, ACIP
Interim Clinical Considerations Update for Pediatric COVID-19 Vaccines
2022
∙
NACI
Interim guidance on planning considerations for a fall 2022 COVID-19 vaccine booster program in Canada
2022
∙
SAGE
Interim recommendations for use of the Cansino Ad5-nCoV-S vaccine (Convidecia ®) against COVID-19
2022
∙
ACIP
Interim Recommendations of the Advisory Committee on Immunization Practices for Use of Moderna and Pfizer-BioNTech COVID-19 Vaccines in Children Aged 6 Months–5 Years
2022
∙
JCVI
JCVI statement on COVID-19 vaccinations in 2022: 21 February 2022
Home
Resources
Diseases
Compendium
Training
Evaluation
SYSVAC
News
Webinars
Network
Sign in / Register
